Evidence map›Paper›PMID 38226422›Full record

ArticleActa obstetricia et gynecologica Scandinavica2024

Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy.

Anna Babkova, Lukas Rob, Martina Kubecova, Martin Hruda, Michael J Halaska

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07551232 (Evaluation of Myocardial Performance Index in Cases of Fetal Anemia), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07551232 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Myocardial Performance Index in Cases of Fetal Anemia: A Prospective Study

TypeobservationalSponsorAssiut UniversityRan2026 to 2028Enrolled15ConditionsFetal Anemia, Fetal Echocardiography
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna BabkovaDepartment of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic.ORCID 0009-0008-9268-6957
Lukas RobDepartment of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic.
Martina KubecovaDepartment of Oncology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic.
Martin HrudaDepartment of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic.
Michael J HalaskaDepartment of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic.
Charles University · CZ

Funding

Third Medical Faculty, Charles University in Prague
6 · The paper itself

Abstract

introductionChemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. MATERIAL AND

methodsThe study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn.

resultsFive patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia.

conclusionsIn four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.

Indexed as

AnemiaAntineoplastic AgentsFetal DiseasesBlood Flow VelocityFemaleHumansInfant, NewbornMiddle Cerebral ArteryPregnancyUltrasonography, PrenatalAntineoplastic Agentschemotherapyfetal anemiamiddle cerebral artery peak systolic velocitypregnancy

Identifiers

PMID38226422
PMCPMC10993339
OpenAlexW4390914030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.